Back to top Open menu arrow
Purchase PDF Reprints

The Journal of
Clinical Psychiatry
Members only

The Journal of Clinical Psychiatry

Consensus Statement November 2, 2026

Ketamine/Esketamine in Clinical Practice: Areas of Consensus and Nonconsensus from an American Society of Clinical Psychopharmacology (ASCP) Delphi Panel Task Force

; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;

J Clin Psychiatry 2027;88(1):26cs16585

Abstract

Objective: Important aspects of ketamine/esketamine treatment for mood disorders in contemporary practice remain inadequately addressed by the current evidence base, necessitating expert guidance in areas where clinical decision needs and implementation have advanced more rapidly than available data. The American Society of Clinical Psychopharmacology convened an expert task force to address unresolved questions about the practical use of these agents in “real-world” settings and potential disparities with evidence-based literature.

Participants: An international panel of 21 academic mood disorder psychopharmacologist-psychiatrists with expertise in ketamine/esketamine clinical care and research.

Evidence: Consensus was reached on 35/105 items (33%), encompassing domains involving diagnostic conditions, contraindications, maximum dosing, racemic versus enantiomeric preparations, oral or intramuscular delivery formulations, laboratory/safety monitoring, access, and parameters for judging treatment outcome.

Consensus Process: Two successive Delphi rounds were completed alongside multiple virtual, email, and in-person meetings. Consensus was defined a priori as ≥75% agreement/disagreement on 5-point Likert survey items. All authors contributed to the interpretation and drafting of recommendations.

Conclusions: Consensus agreement appears elusive for many key decision points involving ketamine/esketamine treatment, reflecting substantial disparities between “real-world” clinical practice and the shortcomings of the clinical trials’ evidence base. Uncertainties persist regarding the use of novel formulations (eg, oral or intramuscular), high-dose ketamine infusions, ketamine-assisted psychotherapy, and use in conditions other than major depression. These areas of expert consensus and dissent lay the groundwork for future studies urgently needed to bridge the gap between evidence-based findings and treatment implementation in routine clinical settings.

J Clin Psychiatry 2027;88(1):26cs16585

Author affiliations are listed at the end of this article.

Also from JCP

Lithium and Prevention of Postpartum Mood Disorder Recurrence Adjunctive Atypical Antipsychotics in Major Depressive Disorder: A Network Meta-Analysis Perspective and Consensus Panel Discussion Thirty Years of the DCPR with Jenny Guidi, PsyD, PhD

From the Editors

New Series The JCP Podcast What if psilocybin's antidepressant effects can persist even when the receptor tied to the trip is blocked? This conversation also digs into real-world data from more than 2,300 regulated psilocybin clients, including a possible dose ceiling and why microdosing may be mostly expectancy.

Members Only Content

This full article is available exclusively to Professional tier members. Subscribe now to unlock the HTML version and gain unlimited access to our entire library plus all PDFs. If you're already a subscriber, please log in below to continue reading.

Subscribe Now

Already a member? Log in

  1. Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47(4):351–354. PubMed
  2. Kritzer MD, Mischel NA, Young JR, et al. Ketamine for treatment of mood disorders and suicidality: a narrative review of recent progress. Ann Clin Psychiatry. 2022;34(1):33–43. PubMed
  3. IQVIA Government Solutions. Trends in Ketamine and Esketamine Dispensing and Administration. Drug Enforcement Administration, Diversion Control Division; 2024:Accessed June 26, 2026. https://www.deadiversion.usdoj.gov/pubs/docs/IQVIA-Ketamine-Esketamine.pdf.
  4. Fava M, Freeman MP, Flynn M, et al. Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Mol Psychiatry. 2018;25(7):1592–1603. PubMed
  5. McIntyre RS, Rosenblat JD, Nemeroff CB, et al. Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation. Am J Psychiatry. 2021;178(5):383–399. PubMed
  6. Sanacora G, Ahmed M, Brown B, et al Real-world safety of esketamine nasal spray: a comprehensive analysis almost 5 years after first approval. Am J Psychiatry 2025:20240655
  7. Fountoulakis KN, Saitis A, Schatzberg AF. Esketamine treatment for depression in adults: a PRISMA systematic review and meta-analysis. Am J Psychiatry. 2025;182(3):259–275. PubMed
  8. Wilkinson ST. Ketamine in the real world: where do we go from here?. J Clin Psychiatry. 2022;83(6):22com14648. PubMed
  9. Abukahok N, Lawrence S, Adhikari S, et al. Monitoring of clinics that use direct-to-consumer advertising for off-label ketamine in the New York metropolitan area: a cross-sectional systematic web search. Fundam Clin Pharmacol. 2026;40(4):e70095.
  10. Wilkinson ST, Toprak M, Turner MS, et al. A survey of the clinical, off-label use of ketamine as a treatment for psychiatric disorders. Am J Psychiatry. 2017;174(7):695–696. PubMed
  11. Kwan ATH, Lakhani M, Rosenblat JD, et al. A global population-based study on the association between ketamine and esketamine with suicidality using WHO VigiBase. J Clin Psychiatry. 2025;86(3):24m15534. PubMed
  12. Kwan ATH, Rosenblat JD, Mansur RB, et al. A replication study using the World Health Organization pharmacovigilance database (VigiBase®) to evaluate whether an association between ketamine and esketamine and alcohol and substance misuse exists. J Affect Disord. 2024;363:589–594. PubMed
  13. McIntyre RS, Mansur RB, Rosenblat JD, et al. The association between ketamine and esketamine and suicidality: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS). Expert Opin Drug Saf. 2025;24(8):909–914. PubMed
  14. Manyara AM, Purvis A, Ciani O, et al. Sample size in multistakeholder Delphi surveys: at what minimum sample size do replicability of results stabilize? J Clin Epidemiol. 2024;174:111485. PubMed
  15. Shang Z. Use of Delphi in health science research. Medicine (Baltim). 2023;102(7):e32829.
  16. Romero-Colado A. Essential elements to elaborate a study with the (e)Delphi method. Enferm Intensiva Engl Ed. 2021;32:100–104.
  17. Logullo P, van Zuuren EJ, Winchester CC, et al. ACcurate COnsensus Reporting Document (ACCORD) explanation and elaboration: guidance and examples to support reporting consensus methods. PLoS Med. 2024;21(5):e1004390. PubMed
  18. Jünger S, Payne SA, Brine J, et al. Guidance on Conducting and REporting DElphi Studies (CREDES) in palliative care: recommendations based on a methodological systematic review. Palliat Med. 2017;31(8):684–706. PubMed
  19. Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med. 1998;17(8):857–872. PubMed
  20. Kwan ATH, Lakhani M, Teopiz KM, et al. Hepatic adverse events associated with ketamine and esketamine: a population-based disproportionality analysis. J Affect Disord. 2025;374:390–396. PubMed
  21. Ng J, Lui LMW, Rosenblat JD, et al. Ketamine-induced urological toxicity: potential mechanisms and translation for adults with mood disorders receiving ketamine treatment. Psychopharmacol Berl. 2021;238(4):917–926.
  22. Singh B, Leung JG, Pazdernik VK, et al. Hepatic safety of ketamine and esketamine for treatment-resistant depression: a real-world cohort study. J Clin Psychopharmacol. 2026.
  23. Shim SR, Jeong HS, Bommersbach TJ, et al. Ketamine infusions and rapid reduction of suicidal and depressive symptoms in major depressive episode: systematic review and meta-analysis. JAMA Psychiatry. 2026;6:e260612.
  24. Schifano J, Niederberger M. How Delphi studies in the health sciences find consensus: a scoping review. Syst Rev. 2025;14(1):14.
  25. Montgomery S. Evidence-based prescribing of antidepressants. Int J Psychiatry Clin Pract. 2003;7(Suppl 1):9–14.
  26. Mathai DS, Cluck M, Aslam AM, et al. Interdisciplinary, Delphi-driven consensus guidelines on the use of intravenous ketamine infusions for depressive disorders from the American Society of Ketamine Physicians, Psychotherapists, and Practitioners (ASKP3). J Affect Disord. 2026;411:121970. PubMed
  27. d’Andrea G, Pettorruso M, Di Lorenzo G, et al. The rapid antidepressant effectiveness of repeated dose of intravenous ketamine and intranasal esketamine: a post-hoc analysis of pooled real-world data. J Affect Disord. 2024;348:314–322. PubMed
  28. Vieta E, Ahmed N, Arango C, et al. Improvements in functioning and workplace productivity with esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression: findings from a 32-week randomised, open-label, rater-blinded phase IIIb study. Eur Neuropsychopharmacol. 2025;93:29–39. CrossRef
  29. Wilkinson ST, Prashad S, Dalthorp R, et al. Non-inferiority, comparative effectiveness study of intravenous ketamine v. intranasal esketamine for treatment-resistant depression: the EQUIVALENCE trial protocol. Contemp Clin Trials. 2026;164:108273. PubMed
  30. Wilkowska A, Wiglusz MS, Jakuszkowiak-Wojten K, et al. Ketamine and lamotrigine combination in psychopharmacology: systematic review. Cells. 2022;11(4):645. PubMed
  31. Veraart JKE, Smith-Apeldoorn SY, Bakker IM, et al. Pharmacodynamic interactions between ketamine and psychiatric medications used in the treatment of depression: a systematic review. Int J Neuropsychopharmacol. 2021;24(10):808–831. PubMed
  32. Feeney A, Hoeppner BB, Freeman MP, et al. Effect of concomitant benzodiazepines on the antidepressant effects of ketamine: findings from the RAPID intravenous ketamine study. J Clin Psychiatry. 2022;84(1):22m14491.
  33. Williams NR, Heifets BD, Blasey C, et al. Attenuation of antidepressant effects of ketamine by opioid receptor antagonism. Am J Psychiatry. 2018;175(12):1205–1215. PubMed
  34. Tucciarone JM, Bandeira ID, Blasey C, et al. Low-dose buprenorphine following ketamine treatment for suicidal ideation in major depressive disorder: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2026;183(6):409–419.
  35. Yermus R, Bottos J, Bryson N, et al. Ketamine-assisted psychotherapy provides lasting and effective results in the treatment of depression, anxiety, and post-traumatic stress disorder at 3 and 6 months: findings from a large retrospective effectiveness study. Psychedelic Med New Rochelle. 2024;2:87–95. PubMed
  36. Moore TM, Walker K, Tung E, et al. Combined ketamine and psychotherapy provide no additional benefit beyond ketamine alone in treating depression or PTSD: evidence from a help-seeking sample. J Affect Disord. 2025;381:233–241. PubMed
  37. Veraart JKE, Schimmers N, Breeksema JJ, et al. Ketamine-assisted psychotherapies for mental disorders: a historical overview and systematic review. Clin Psychol Rev. 2026;124:102706. PubMed
  38. Drozdz S, Goel A, McGarr MW, et al. Ketamine assisted psychotherapy: systematic narrative review of the literature. J Pain Res. 2022;15:1691–1706. PubMed
  39. Kwonmok K, Knight G, Rucker JJ, et al. Psychedelics, mystical experience, and therapeutic efficacy: a systematic review. Front Psychiatry. 2022;13:917199. PubMed
  40. Glue P, Loo C, Fam J, et al. Extended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trial. Nat Med. 2024;30(7):2004–2009. PubMed
  41. Walter M, zu Eulenberg C, Damyanova A, et al. Oral prolonged-release ketamine for treatment-resistant depression: two randomized clinical trials. JAMA Netw Open. 2026;9(6):e2619121. PubMed
  42. Shenoy S, Belle VS, Munoli RN, et al. Short-term effects of oral ketamine for the treatment of depression: a systematic review and meta-analysis of randomized controlled trials. Asian J Psychiatry. 2026;121:105014.
  43. Silberbauer LR, Eggerstorfer B, Michenthaler P, et al. Oral ketamine for the treatment of major depressive and bipolar disorder, a randomized controlled trial and meta-analysis. J Affect Disord. 2026;394(Pt A):120466. PubMed
  44. Fava M, Berkowitz O, Mathew SJ, et al. CLEO: a phase 2 randomized controlled adjunctive treatment trial with CLE-100 esketamine tablet for patients with major depressive disorder and inadequate response to antidepressants, during the COVID-19 pandemic. In: Poster presented at the annual meeting of the American Society of Clinical Psychopharmacology, Miami FL; 2023.
  45. Horwitz RI, Singer BH. Why evidence-based medicine failed in patient care and medicine-based evidence will succeed. J Clin Epidemiol. 2017;84:14–17. PubMed
  46. Horwitz RI, Hayes-Conroy A, Caricchio R, et al. From evidence based medicine to medicine based evidence. Am J Med. 2017;130(11):1246–1250. PubMed
  47. Horn SD, Gassaway J. Practice based evidence: incorporating clinical heterogeneity and patient-reported outcomes for comparative effectiveness research. Med Care. 2010;48(6 Suppl):S17–S22. PubMed
  48. Pacilio RM, Parikh SVM, Gellar J. Outpatient ketamine prescribing practices in psychiatry in the United States: a nationwide survey study. J Clin Psychiatry. 2025;86(25):m150809.
  49. Harding L. Regulating ketamine use in psychiatry. J Am Acad Psychiatry L. 2023;51(3):320–325.
  50. Akins RB, Tolson H, Cole BR. Stability of response characteristics of a Delphi panel: application of bootstrap data expansion. BMC Med Res Methodol. 2005;5:37.

About the Authors

Buy PDF for $40

Please sign in or purchase this PDF for $40.

The Journal of Clinical Psychiatry September 2026 cover featuring key articles on depression therapy

Vol 87 • 2026 • Number 3

Read the Current Issue

Original Research

Inhaled Mebufotenin (GH001) for Adult Patients with Postpartum Depression

Original Research

US Mortality Involving Obesity and Psychiatric Disorders

Academic Highlights

Treatment-Resistant Depression as a Dynamic Continuum: A Consensus Panel Report

Original Research

Effects of Brexpiprazole on Functioning in Patients with Schizophrenia Who Have Hostility and Agitation Symptoms

Original Research

Exposure-Based Video Therapy for OCD and PTSD

Original Research

Lumateperone as Adjunctive Therapy in Patients With Major Depressive Disorder and Anxious Distress
View current Issue

Insightful. Evidence-based. Human-centered.

Listen Now
Psychiatrist Steven Berkowitz, MD, discusses psychedelic medicine for trauma treatment

Subscribe to read
more articles

Subscribe